371 results on '"Iriyama, Noriyoshi"'
Search Results
2. Clinical management of second-generation tyrosine kinase inhibitor therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase, focusing on age and dose effects
3. Importance of TKI treatment duration in treatment-free remission of chronic myeloid leukemia: results of the D-FREE study
4. Nilotinib vs dasatinib in achieving MR4.5 for de novo chronic myeloid leukemia: the randomized JALSG CML212 study
5. Chronic myeloid leukemia: the cutting-edge evidence and things we should know
6. A Higher Neutrophil Count Is Associated with Favorable Achievement of Treatment-Free Remission in Patients with Chronic Myeloid Leukemia Who Received Second Generation Tyrosine Kinase Inhibitor as Frontline Treatment.
7. RUNX1::RUNX1T1 Acute Myeloid Leukemia Cytogenetically Showing t(6;8)(p23;q22)
8. An observational study of once-weekly carfilzomib in patients with multiple myeloma in Japan (Weekly-CAR study)
9. Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11
10. JSH Practical Guidelines for Hematological Malignancies, 2018: I. Leukemia-4. Chronic myeloid leukemia (CML)/myeloproliferative neoplasms (MPN)
11. PB2301: OPTIMAL DOSE INTENSITY OF R-CHOP FOR PATIENTS WITH DLBCL AGED 80 YEARS OR OLDER: IS THE R-MINICHOP A GOLD STANDARD?
12. One percent chlorhexidine-alcohol for preventing central venous catheter-related infection during intensive chemotherapy for patients with haematologic malignancies
13. Enhanced perforin expression associated with dasatinib therapy in natural killer cells
14. Regulatory T cell inhibition by dasatinib is associated with natural killer cell differentiation and a favorable molecular response—The final results of the D-first study
15. Efficacy and safety of tyrosine kinase inhibitors for newly diagnosed chronic-phase chronic myeloid leukemia over a 5-year period: results from the Japanese registry obtained by the New TARGET system
16. Features of vascular adverse events in Japanese patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a retrospective study of the CML Cooperative Study Group database
17. Incidences and outcomes of therapy-related chronic myeloid leukemia in the era of tyrosine kinase inhibitors: Surveillance of the CML Cooperative Study Group
18. Increased Arbekacin Clearance in Patients With Febrile Neutropenia
19. Thrombopoietin Levels During Tyrosine Kinase Inhibitor Therapy for Chronic Myeloid Leukemia
20. MPC-1 expression in myeloma cells is associated with the efficacy of bortezomib therapy
21. Chronic myeloid leukemia: the cutting-edge evidence and things we should know
22. Clinical entity of cytomegalovirus disease in patients with malignant lymphoma on bendamustine therapy: a single-institution experience
23. A cyclin D1-negative mantle cell lymphoma with an IGL-CCND2 translocation that relapsed with blastoid morphology and aggressive clinical behavior
24. von Willebrand factor activity levels are influenced by driver mutation status in polycythemia vera and essential thrombocythemia patients with well‐controlled platelet counts
25. New Molecular-Targeting Therapy for Chronic Myeloid Leukemia
26. Pirarubicin‐based intensive chemotherapy followed by consolidative high‐dose chemotherapies for peripheral T‐cell lymphomas: A noncomparative phase 2 study
27. Comparison of the clinical outcomes of nilotinib and dasatinib therapies in newly diagnosed patients in the chronic phase of chronic myeloid leukemia: a retrospective analysis
28. Incidence and outcome of second malignancies in patients with chronic myeloid leukemia during treatment with tyrosine kinase inhibitors
29. Efficacy and safety of nilotinib therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase
30. Plasma cell maturity as a predictor of prognosis in multiple myeloma
31. Clinical efficacy and safety of arbekacin for high-risk infections in patients with hematological malignancies
32. Outcomes of adolescents and young adults with chronic-phase chronic myeloid leukaemia treated with tyrosine kinase inhibitors
33. Ideal dose intensity of R-CHOP in diffuse large B-cell lymphoma
34. CD56 expression is an independent prognostic factor for relapse in acute myeloid leukemia with t(8;21)
35. Clinical entity of cytomegalovirus disease in patients with malignant lymphoma on bendamustine therapy: a single-institution experience.
36. Dose-intensified CHOP with rituximab (R-Double-CHOP) followed by consolidation high-dose chemotherapies for patients with advanced diffuse large B-cell lymphoma
37. Clinical impact of central nervous system‐directed therapies on intravascular large B‐cell lymphoma: A single institution's experience
38. The European Treatment and Outcome Study score is associated with clinical outcomes and treatment response following European LeukemiaNet 2013 recommendations in chronic-phase chronic myeloid leukemia
39. Perspective on Therapeutic Strategies of Leukemia Treatment — Focus on Arsenic Compounds
40. Efficacy and safety of antifungal prophylaxis with oral itraconazole solution among patients receiving corticosteroids: who should be given prophylaxis?
41. Relationship between Carnitine Deficiency and Tyrosine Kinase Inhibitor Use in Patients with Chronic Myeloid Leukemia
42. Nilotinib and Dasatinib Evoked Distinct Immune Effects during Tfr Phase of Each Discontinuation Trial
43. Importance of the Duration of TKI Treatment in Treatment-Free Remission of Chronic Phase Chronic Myeloid Leukemia: Results of D-Free Trial
44. Normal karyotype acute myeloid leukemia with the CD7+ CD15+ CD34+ HLA-DR + immunophenotype is a clinically distinct entity with a favorable outcome
45. Absolute Lymphocyte Counts After Lenalidomide Initiation may Predict the Prognosis of Patients With Relapsed or Refractory Multiple Myeloma
46. Early cytotoxic lymphocyte expansion contributes to a deep molecular response to dasatinib in patients with newly diagnosed chronic myeloid leukemia in the chronic phase: results of the D-first study
47. Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: Results of the D-first study of Kanto CML study group
48. Maintenance Therapy With Bortezomib and Dexamethasone for Transplant-ineligible Patients With Multiple Myeloma
49. Personalized patient care with aggressive hematological malignancies in non-responders to first-line treatment
50. Charlson Comorbidity Index is an independent prognostic factor among elderly patients with diffuse large B-cell lymphoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.